Peptide Receptor Radionuclide Therapy

J Clin Endocrinol Metab. 2022 Oct 5:dgac574. doi: 10.1210/clinem/dgac574. Online ahead of print.ABSTRACTThe concept of using a targeting molecule labeled with a diagnostic radionuclide for using PET or SPECT imaging with the potential to demonstrate that tumoricidal radiation can be delivered to tumoral sites by administration of the same or a similar targeting molecule labeled with a therapeutic radionuclide is named "theranostics". Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs (SSAs) is a well-established second/third-line theranostic treatment for somatostatin receptor-positive well-differentiated (neuro-)endocrine neoplasms (NENs). PRRT with 177Lu-DOTATATE was approved by the regulatory authorities in 2017 & 2018 for selected patients with low-grade well-differentiated gastroenteropancreatic (GEP) NENs. It improves progression-free survival as well as quality of life of GEP NEN patients. Favorable symptomatic and biochemical responses using PRRT with 177Lu-DOTATATE have also been reported in patients with functioning metastatic GEP NENs like metastatic insulinomas, VIPomas, glucagonomas, gastrinomas and patients with carcinoid syndrome. This therapy might also become a valuable therapeutic option for inoperable low grade bronchopulmonary (BP) NENs, inoperable, or progressive pheochromocytomas and paragangliomas and medullary thyroid carcinomas. First-line PRRT with 177Lu-DOTATATE and combinations of this therapy with cytotoxic dru...
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Source Type: research